CN1772016A - Medicine prepn for treating cerebral apoplexy and its prepn - Google Patents
Medicine prepn for treating cerebral apoplexy and its prepn Download PDFInfo
- Publication number
- CN1772016A CN1772016A CN 200410079556 CN200410079556A CN1772016A CN 1772016 A CN1772016 A CN 1772016A CN 200410079556 CN200410079556 CN 200410079556 CN 200410079556 A CN200410079556 A CN 200410079556A CN 1772016 A CN1772016 A CN 1772016A
- Authority
- CN
- China
- Prior art keywords
- extract
- radix seu
- seu caulis
- caulis embeliae
- embeliae parviflorae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to one kind of medicine prepared with effective medicinal components extracted from natural plant material and has cerebral vascular disease treating effect and its preparation process. The medicine preparation for treating cerebral apoplexy consists of alcohol or water extract of speedwell and medicinal supplementary material. The preparation process includes the following steps: washing and crushing medicine material speedwell; hot reflux extraction with alcohol solution or water or decoction and other steps to obtain extractum or powder; and mixing with supplementary material. The medicine of the present invention has high curative effect on apoplexy and apoplexy caused hemiplegia, numbness of limbs, facial hemiplegia, etc.
Description
Technical field
The present invention relates to a kind of by the effective medicinal ingredient that extracts in the natural plant crude drugs make to medicative medicine of cerebrovascular disease and preparation method.
Background technology
Cerebrovascular disease is one of human three big causes of the death, and the survivor half leaves sequela, is directly threatening the health of middle-aged and elderly people, and the cerebrovascular disease patient also has the trend of increase in person between twenty and fifty now.The body-building of the prevention of cerebrovascular disease and treatment, middle-aged and elderly people is at present prolonged life, the protection of between twenty and fifty people's cerebral ischemia has become the important topic of society and medical circle extensive concern, and country also is placed on critical positions to the development of treatment Chinese Traditional Medicines new product, novel form.Aspect the treatment of cerebrovascular disease, treat National Drug Administration and all set up detailed criterion and guideline from diagnosing to, appearing on the market of the particularly use of modern instrument, and newtype drug improved diagnosis and treatment rate to cerebrovascular disease.The doctor trained in Western medicine medication can reduce four big classes: beta-Blocking agent, Ca antagonist and vasodilator, diuretic, antithrombotic, and wherein very fast with second class and the development of the 4th class, as nimodipine, streptokinase, urokinase, tPA, reptilase etc.Though these product curative effects, cost an arm and a leg certainly, side effect is big; The Chinese patent medicine aspect, our country has developed some Chinese patent medicines in recent years in succession, as Radix Salviae Miltiorrhizae, Rhizoma Chuanxiong, gingko injection, Breviscapini injection (sheet) and traditional BUYANG HUANWU TANG, HUATUO ZAIZAO WAN etc., also have some tools health cares and therapeutical effect as NIAOXUEKANG, Xantinol Nicotinate, embolism extinguishing oral liquid etc., though these medicines have certain curative effect, majority is for crude extract or have many deficiencies.The ideal medicament that is used for the treatment of cerebrovascular disease at present is less, demands research urgently.
Summary of the invention
It is the pharmaceutical preparation of the treatment apoplexy disease of effective medicinal ingredient preparation with Radix seu Caulis Embeliae Parviflorae extract that purpose of the present invention aims to provide a kind of.
Another object of the present invention provides the preparation method of the pharmaceutical preparation of this treatment apoplexy disease.
The pharmaceutical preparation of treatment apoplexy disease of the present invention is grouped into by following one-tenth: Radix seu Caulis Embeliae Parviflorae extract and pharmaceutic adjuvant.
The pharmaceutical preparation of treatment apoplexy disease of the present invention is made up of following component in percentage by weight: the pharmaceutic adjuvant of Radix seu Caulis Embeliae Parviflorae extract 20-60% and surplus.
The used raw medicinal material of the present invention is the whole herb with root of Radix seu Caulis Embeliae Parviflorae, and described Radix seu Caulis Embeliae Parviflorae extract is Radix seu Caulis Embeliae Parviflorae alcohol extract or the water extract of 10%-80% for the total flavones percentage composition.
Described pharmaceutic adjuvant is meant the pharmaceutic adjuvant of pharmaceutical field routine.
The used medical material Radix seu Caulis Embeliae Parviflorae of this extract is the whole herb with root of Primulaceae Radix seu Caulis Embeliae Parviflorae Lysimachia barystachys Bung. or short peach Lysimachia clethroides Duby.In D.C.; collecting season is generally 7-9 month; wind-induced hemiplegia during it reaches the treatment apoplexy; numb limbs and tense tendons; facial hemiparalysis; speech is unfavorable to wait disease that curative effect is preferably arranged; Radix seu Caulis Embeliae Parviflorae is through the plant analysis; mainly contain flavone compound; preliminary pharmacodynamics shows; its alcohol extract has significant diastole effect to the Medulla Bovis seu Bubali tremulous pulse bar that exsomatizes; significantly increase rabbit carotid artery and cerebral blood flow, to acute pulmonary embolism due to the arachidonic acid antithrombotic; respiratory distress and death have obvious protective effect.
The use amount of medicine of the present invention can be according to variations such as the type of route of administration, patient's age, body weight, the disease of being treated and the orders of severity, its day clothes dosage can be 20～120mg/ man day.The pharmaceutical preparation of treatment apoplexy disease of the present invention is the tablet made by known method, thin membrane coated tablet, oral controlled-release agent, coated tablet, capsule, soft capsule, granule, oral liquid, buccal agent, injection etc.
The preparation method of the pharmaceutical preparation of treatment apoplexy disease of the present invention is made up of following steps:
One, carries out coarse pulverization after getting Radix seu Caulis Embeliae Parviflorae medical material cleaning;
Two, add the solvent thermal reflux, extract, that 4-12 doubly measures or boil and put forward, described solvent is ethanol or the water of 10-95%, and backflow 1-3 hour, merge extractive liquid, reclaimed solvent, fluid extract or extract dry powder;
Three, with after fluid extract or extract dry powder and the auxiliary materials and mixing, make pharmaceutical preparation.
Perhaps
One, carries out coarse pulverization after getting Radix seu Caulis Embeliae Parviflorae medical material cleaning;
Two, add the solvent thermal reflux, extract, that 4-12 doubly measures or boil and put forward, described solvent is ethanol or the water of 10-95%, and backflow 1-3 hour, merge extractive liquid, reclaimed solvent;
Three, reclaim the water that 1-4 that extractum behind the solvent adds the medical material amount doubly measures, be chilled to room temperature after boiling, use membrane filtration, the 1-4 that filtrate is pressed the medical material amount doubly goes up macroporous adsorptive resins, uses 1-20% alcoholic solution, 30-100% alcoholic solution eluting successively;
When four, eluent reclaims and to be concentrated into proportion behind the ethanol and to be 60 ℃ 1.30 or more after, 40 ℃ of-90 ℃ of vacuum dryings, pulverizing is sieved, and promptly gets extract powder;
Five, with after extract powder and the auxiliary materials and mixing, make pharmaceutical preparation.
The assay of effective component extracts in the pharmaceutical preparation of the present invention:
1. the preparation of reference substance solution: precision takes by weighing 120 ℃ of rutin standard substance 50mg that are dried to constant weight, place the 50ml volumetric flask, it is an amount of to add methanol, and slight fever makes its dissolving, puts cold back and is diluted to scale with methanol, shake up, precision is measured 20ml, puts in the 100ml volumetric flask, is diluted with water to scale, shake up, promptly get (every 1ml contains rutin 0.2mg).
The preparation of standard curve: precision is measured reference substance solution 0.0,1.0,2.0,3.0,4.0,5.0,6.0,7.0,8.0ml place the 25ml volumetric flask, respectively add 5% sodium nitrite solution 1ml, shaking up the back placed 6 minutes, add 10% aluminum nitrate solution 1ml, shake up, put 6 minutes again, and added 4% sodium hydroxide 10ml, thin up is to scale respectively, shake up, placed 15-20 minute, and, did blank with reference substance solution 0.0ml sample according to spectrophotography (2000 editions appendix V of Chinese Pharmacopoeia), measure trap at the 500nm place, with the trap is vertical coordinate, and concentration is abscissa, the drawing standard curve.
Assay: precision takes by weighing this product 30mg, adds 60% dissolve with ethanol, places the 100ml volumetric flask, and is diluted to scale, shakes up filtration; The accurate subsequent filtrate 5ml that draws presses standard curve method in the 25ml volumetric flask, the preparation need testing solution is measured trap at the 500nm place, reads rutin content in the test sample by standard curve, calculates, and promptly gets general flavone content.
2. according to high performance liquid chromatography (" 2000 editions appendix VID of Chinese pharmacopoeia)
Chromatographic condition and systematicness test: with octadecylsilane chemically bonded silica is filler, acetonitrile-oxolane-0.1% phosphoric acid solution (14: 2: 84), and the detection wavelength is 350nm, theoretical cam curve is calculated by the hyperin absworption peak should be not less than 3000.
The preparation of reference substance solution: precision takes by weighing hyperin 10mg, places the 50ml volumetric flask, and it is an amount of to add methanol, and slight fever makes its dissolving, puts cold back and is diluted to scale with methanol, shakes up, and promptly gets (every 1ml contains hyperin 0.2mg).
The preparation of need testing solution: get this product 70mg, the accurate title, decide, and with moving in the 25ml volumetric flask after the small amount of methanol dissolving, adds methanol and be diluted to scale, shakes up, and filters, as need testing solution.
Algoscopy: accurate reference substance solution and each 10ul of need testing solution of drawing, inject chromatograph of liquid, measure, promptly.
The toxicologic study of pharmaceutical preparation of the present invention:
Toxicologic study shows, the maximum tolerated dose that per os gives Radix seu Caulis Embeliae Parviflorae extract is respectively: rat＞7.5g/kg, mice＞12.5g/kg.Beale Canis familiaris L. by 105,210, the 420mg/kg oral dose, rat by 0.35,0.70,1.40g/kg irritates stomach, continuous 6 months, hematology and biochemical indicator no abnormality seen, pathological examination is no abnormality seen also, learns check by statistics, compares there was no significant difference with sky from group.
The pharmacodynamic study of pharmaceutical preparation of the present invention:
1. Radix seu Caulis Embeliae Parviflorae extract is to the influence of focal cerebral ischemia in rats
With electrocoagulation blocking-up rat brain medium-sized artery, cause the focal cerebral ischemia model, observe the therapeutical effect of Radix seu Caulis Embeliae Parviflorae extract to focal cerebral ischemia.The result shows, compares with model group, and focus of infarct obviously dwindles after the administration of Radix seu Caulis Embeliae Parviflorae extract group rat preduodenal, and the neurobehavioral obstacle of animal obviously alleviates behind the cerebral infarction, and blood plasma ET content obviously reduces.Show that Radix seu Caulis Embeliae Parviflorae extract has the obvious treatment effect to focal cerebral ischemia in rats.
2. Radix seu Caulis Embeliae Parviflorae extract is to the influence of anesthetized dog cerebral blood flow
With the ICAF amount is main observation index, observes the influence of Radix seu Caulis Embeliae Parviflorae extract to the animal brain blood flow.Experimental result shows that Radix seu Caulis Embeliae Parviflorae extract can obviously increase anesthetized dog cerebral blood flow (CBF), reduces cerebral vascular resistance (CVR); Arteriotony (SP, DP, MAP), heart rate (HR), electrocardiogram (ECG-II) there is not obviously influence.
3. Radix seu Caulis Embeliae Parviflorae extract is to the influence of cerebral ischemia
Use the cerebral ischemia model, observe the influence of Radix seu Caulis Embeliae Parviflorae extract rat brain water content and cerebral tissue SOD vigor, MDA content.The result shows that brain water content obviously raises behind the ischemia-reperfusion, and cerebral tissue SOD vigor obviously reduces, MDA content raises, and causes brain tissue impairment, and permeability strengthens.After duodenum gave Radix seu Caulis Embeliae Parviflorae extract, brain water content obviously reduced, and tissue SOD's vigor obviously strengthens, MDA content obviously reduces, with model group comparing difference remarkable (P＜0.05).Show that Radix seu Caulis Embeliae Parviflorae extract has protective effect to cerebral ischemia reperfusion injury.
4. Radix seu Caulis Embeliae Parviflorae extract is to the influence of rabbit platelet aggregation
Adopt the BornShi turbidimetry, observe the influence of Radix seu Caulis Embeliae Parviflorae extract the rabbit platelet aggregation.Result of the test shows, continuous 7 days gastric infusions of rabbit, Radix seu Caulis Embeliae Parviflorae extract obviously reduce adenosine diphosphate (ADP) (ADP), arachidonic acid (AA) and the inductive rabbit platelet aggregation rate of platelet activating factor (PAF) (P＜0.05-0.001).Show that Radix seu Caulis Embeliae Parviflorae extract has the effect of obvious anticoagulant.
5. Radix seu Caulis Embeliae Parviflorae extract is to the influence of rats in vitro thrombosis and blood viscosity
The experimental observation Radix seu Caulis Embeliae Parviflorae extract is to the influence of rats in vitro thrombosis and blood viscosity.The result shows: continuous 7 days gastric infusions of rat, Radix seu Caulis Embeliae Parviflorae extract significantly shorten thrombosis length ((P＜0.01 ∽ 0.001), alleviate wet weight of thrombus and dry weight (P＜0.01 ∽ 0.001); Reduce shear rate 100S
-1, 30S
-1, 5S
-1Under whole blood viscosity (P＜0.05 ∽ 0.001).Show that Radix seu Caulis Embeliae Parviflorae extract has the effect that suppresses thrombosis, blood viscosity lowering.
6. Radix seu Caulis Embeliae Parviflorae extract influences rat's pial microcirculation
Cause the rat's pial microcirculation disturbance by injecting 15% high molecular dextran, observe of the influence of Radix seu Caulis Embeliae Parviflorae extract duodenal administration the rat microcirculation disturbance.The result shows, Radix seu Caulis Embeliae Parviflorae extract all can obviously increase velocity of blood flow in the period of observed 10,20,30min, improve the blood fluidised form, with model group significant difference is arranged more all.Show that Radix seu Caulis Embeliae Parviflorae extract has the effect that improves the rat's pial microcirculation disturbance.
The general pharmacology of pharmaceutical preparation of the present invention is learned research:
1, its mouse oral gives Radix seu Caulis Embeliae Parviflorae extract 960,480,240mg/kg dosage respectively, spiritual nervous system to mice does not have obvious influence, similar to the distilled water matched group (P＞0.05), its general behavior, pupil, posture, gait, stream birth, amyostasia, autonomic activities number and every observation index all do not have any obvious influence; There is not synergism with subliminal hypnosis dosage pentobarbital sodium, its average time for falling asleep identical with the length of one's sleep (P＞0.05) with the distilled water matched group yet.
2, cat respectively per os give Radix seu Caulis Embeliae Parviflorae extract 288,144,72mg/kg dosage, cardiovascular and respiratory system to cat do not have obvious influence, its mean arterial pressure, respiratory frequency, amplitude of respiration and Electrocardiographic heart rate, P ripple, R ripple, T ripple, QRS wave group, S-T displacement, P-R interval, Q-T interval etc. every index all similar (P＞0.05) to the distilled water matched group.
The specific embodiment
Embodiment 1:
1, carries out coarse pulverization after the Radix seu Caulis Embeliae Parviflorae medical material cleaning;
2, get above-mentioned coarse pulverization medical material, add 40% alcohol heat reflux and extract secondary, add 8 times of amounts at every turn, refluxed 2 hours at every turn, merge first and second extracting solution and reclaim ethanol;
3, the extractum behind the recovery ethanol adds the water of 2 times of amounts of medical material amount, is chilled to room temperature after boiling, and uses membrane filtration, and filtrate is pressed 2 times of last macroporous adsorptive resins of medical material amount, and water, 10% ethanol are washed successively, 70% ethanol elution;
4, being concentrated into proportion behind the eluent recovery ethanol is the above back 80 ℃ of vacuum dryings of 1.30 (60 ℃), pulverizes, and crosses 80 mesh sieves, promptly gets extract powder;
5, the extract powder yield 1.92%, and wherein general flavone content is 58.50%, and hyperin content is 4.31%, organic solvent residual meets the regulation of relevant resin organic solvent residual thing in the new drug reviewing way in the macroporous adsorbent resin, with above-mentioned extract powder 40%, starch 30%, Celluloasun Microcrystallisatum 30% mixes, put grinding in ball grinder 2 hours, cross 120 mesh sieves, abundant mixing, inspect by ready samples qualified after, divide to be packed in the capsulae vacuus, promptly get required Radix seu Caulis Embeliae Parviflorae capsule.
Embodiment 2:
1, carries out coarse pulverization after the Radix seu Caulis Embeliae Parviflorae medical material cleaning;
2, above-mentioned coarse pulverization medical material is added 60% alcohol heat reflux and extract secondary, add 10 times of amounts at every turn, refluxed 2 hours at every turn, merge first and second extracting solution and reclaim ethanol, get extractum;
3, the extractum behind the recovery ethanol adds the water of 3 times of amounts of medical material amount, is chilled to room temperature after boiling, and uses membrane filtration, and filtrate is pressed 2 times of last macroporous adsorptive resins of medical material amount, and water, 10% ethanol are washed successively, 80% ethanol elution;
4, being concentrated into proportion behind the eluent recovery ethanol is the above back 60 ℃ of vacuum dryings of 1.30 (60 ℃), pulverizes, and crosses 80 mesh sieves, promptly gets extract powder;
5, the extract powder yield 2.08%, wherein general flavone content is 59.36%, hyperin content is the regulation that organic solvent residual meets relevant resin residue thing in the new drug reviewing way in the 4.28%. macroporous adsorbent resin, extract powder is dissolved in the hydrogenated vegetable oil, both weight ratios are 1: 5, be uniform grease, adopt rotation rolling capsule machine or soft gelatin capsule dropping preparation method automatically then, promptly get required Radix seu Caulis Embeliae Parviflorae soft capsule preparation..
Embodiment 3:
1, carries out coarse pulverization after the Radix seu Caulis Embeliae Parviflorae medical material cleaning;
2, take by weighing above-mentioned coarse pulverization medical material and add 80% alcohol heat reflux extraction secondary, add 8 times of amounts at every turn, refluxed 2 hours at every turn, merge first and second extracting solution and reclaim ethanol, get extractum;
3, the extractum behind the recovery ethanol adds the water of 4 times of amounts of medical material amount, is chilled to room temperature after boiling, and uses membrane filtration, and filtrate is pressed 4 times of last macroporous adsorptive resins of medical material amount, and water, 10% ethanol are washed successively, 95% ethanol elution;
4, being concentrated into proportion behind the eluent recovery ethanol is the above back 70 ℃ of vacuum dryings of 1.30 (60 ℃), pulverizes, and crosses 80 mesh sieves, promptly gets extract powder;
5; extract powder yield 2.36%; wherein general flavone content is 62.91%; hyperin content is the regulation that organic solvent residual meets relevant resin residue thing in the new drug reviewing way in the 5.27%. macroporous adsorbent resin; with above-mentioned extract powder 40%; starch 60% mixes; put grinding in ball grinder 2 hours; cross 120 mesh sieves; abundant mixing; making granularity through dry granulation or one-step-granulating method is 40-80 purpose granule, adds the magnesium stearate of particle weight 0.5%-1.0% in dried granule, and compacting in flakes behind the mixing granulate; behind the bag film-coat, promptly get required Radix seu Caulis Embeliae Parviflorae tablet.
Embodiment 4:
Extracting method by embodiment 1 gets extract powder, with extract powder 40%, and starch 30%, Celluloasun Microcrystallisatum 30% mixes, put grinding in ball grinder 2 hours, and crossed 120 mesh sieves, fully mixing, inspect by ready samples qualified after, divide to be packed in the capsulae vacuus, promptly get required Radix seu Caulis Embeliae Parviflorae capsule.
Embodiment 5:
1, carries out coarse pulverization after the Radix seu Caulis Embeliae Parviflorae medical material cleaning;
2, take by weighing above-mentioned coarse pulverization medical material and add 40% alcohol heat reflux extraction secondary, add 8 times of amounts at every turn, refluxed 2 hours at every turn, merge first and second extracting solution and reclaim ethanol, get extractum;
3, the extractum behind the recovery ethanol adds the water of 2 times of amounts of medical material amount, is chilled to room temperature after boiling, and uses membrane filtration, and filtrate is pressed 3 times of last macroporous adsorptive resins of medical material amount, and water, 10% ethanol are washed successively, 70% ethanol elution;
4, after eluent reclaims and to be concentrated into proportion behind the ethanol and to be 1.25 (60 ℃) runny plaste, add dextrin in runny plaste and 1: 1 ratio of adjuvant weight ratio and carry out spray-drying process, Teng's principle makes that extractum mixes with adjuvant, granulation, drying are finished simultaneously to utilize extractum spraying and fluidized bed to boil, and promptly gets required Radix seu Caulis Embeliae Parviflorae granule.
Embodiment 6:
Extracting method by embodiment 2 gets extract powder, gets 200 milliliters of distilled water for injection, and the adding tween 80 is an amount of, add 2 gram Radix seu Caulis Embeliae Parviflorae extractum powders again, heating for dissolving, filtration, packing, sterilization, make every milliliter of Radix seu Caulis Embeliae Parviflorae injection that contains 5 milligrams of total flavones, be sub-packed in ampoule.
Embodiment 7:
Extracting method by embodiment 2 gets extract powder, gets 200 milliliters of distilled water for injection, adds 20 gram Radix seu Caulis Embeliae Parviflorae extractum powders, 2g glucose, heating for dissolving, and every bottle of Radix seu Caulis Embeliae Parviflorae lyophilized injectable powder that contains 50 milligrams of total flavones is made in filtration, lyophilization.
Embodiment 8:
1, carries out coarse pulverization after the Radix seu Caulis Embeliae Parviflorae medical material cleaning;
2, get above-mentioned coarse pulverization medical material, add decocting in water and carry secondary, add 8 times of amounts at every turn, refluxed 2 hours at every turn, merge first and second extracting solution;
3, after extracting solution is chilled to room temperature, use membrane filtration, filtrate is pressed 2 times of last macroporous adsorptive resins of medical material amount, and water, 10% ethanol are washed successively, 70% ethanol elution;
4, being concentrated into proportion behind the eluent recovery ethanol is the above back 80 ℃ of vacuum dryings of 1.30 (60 ℃), pulverizes, and crosses 80 mesh sieves, promptly gets extract powder;
5, the extract powder yield 3.05%, and wherein general flavone content is 48.63%, and hyperin content is 3.46%, organic solvent residual meets the regulation of relevant resin organic solvent residual thing in the new drug reviewing way in the macroporous adsorbent resin, with above-mentioned extract powder 40%, starch 30%, Celluloasun Microcrystallisatum 30% mixes, put grinding in ball grinder 2 hours, cross 120 mesh sieves, abundant mixing, inspect by ready samples qualified after, divide to be packed in the capsulae vacuus, promptly get required Radix seu Caulis Embeliae Parviflorae capsule.
Claims (6)
1, a kind of pharmaceutical preparation for the treatment of the apoplexy disease is characterized in that being grouped into by following one-tenth: Radix seu Caulis Embeliae Parviflorae extract and pharmaceutic adjuvant.
2, the pharmaceutical preparation of treatment apoplexy disease as claimed in claim 1 is characterized in that being made up of following component in percentage by weight: the pharmaceutic adjuvant of Radix seu Caulis Embeliae Parviflorae extract 20-60% and surplus.
3,, it is characterized in that described Radix seu Caulis Embeliae Parviflorae extract is Radix seu Caulis Embeliae Parviflorae alcohol extract or water extract as the pharmaceutical preparation of claim 1 and 2 described treatment apoplexy diseases.
4, as the pharmaceutical preparation of claim 1,2,3 described treatment apoplexy diseases, it is characterized in that described Radix seu Caulis Embeliae Parviflorae is the whole herb with root of Radix seu Caulis Embeliae Parviflorae, the total flavones percentage composition is 10%-80%.
5, the preparation method of the pharmaceutical preparation of treatment apoplexy disease as claimed in claim 1 is characterized in that being made up of following steps:
One, carries out coarse pulverization after getting Radix seu Caulis Embeliae Parviflorae medical material cleaning;
Two, add the solvent thermal reflux, extract, that 4-12 doubly measures or boil and put forward, described solvent is ethanol or the water of 10-95%, and backflow 1-3 hour, merge extractive liquid, reclaimed solvent, fluid extract or extract dry powder;
Three, with after fluid extract or extract dry powder and the auxiliary materials and mixing, make pharmaceutical preparation.
6, the preparation method of the pharmaceutical preparation of treatment apoplexy disease as claimed in claim 1 is characterized in that being made up of following steps:
One, carries out coarse pulverization after getting Radix seu Caulis Embeliae Parviflorae medical material cleaning;
Two, add the solvent thermal reflux, extract, that 4-12 doubly measures or boil and put forward, described solvent is 10%-95% ethanol or water, and backflow 1-3 hour, merge extractive liquid, reclaimed solvent;
Three, reclaim the water that 1-4 that extractum behind the solvent adds the medical material amount doubly measures, be chilled to room temperature after boiling, use membrane filtration, the 1-4 that filtrate is pressed the medical material amount doubly goes up macroporous adsorptive resins, uses 1-20% alcoholic solution, 30-100% alcoholic solution eluting successively;
When four, eluent reclaims and to be concentrated into proportion behind the ethanol and to be 60 ℃ 1.30 or more after, 40 ℃ of-90 ℃ of vacuum dryings, pulverizing is sieved, and promptly gets extract powder;
Five, with after extract powder and the auxiliary materials and mixing, make pharmaceutical preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100795560A CN100358530C (en) | 2004-11-11 | 2004-11-11 | Medicine prepn for treating cerebral apoplexy and its prepn |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100795560A CN100358530C (en) | 2004-11-11 | 2004-11-11 | Medicine prepn for treating cerebral apoplexy and its prepn |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1772016A true CN1772016A (en) | 2006-05-17 |
| CN100358530C CN100358530C (en) | 2008-01-02 |
Family
ID=36759267
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100795560A Expired - Fee Related CN100358530C (en) | 2004-11-11 | 2004-11-11 | Medicine prepn for treating cerebral apoplexy and its prepn |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100358530C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009091121A3 (en) * | 2008-01-18 | 2009-09-03 | Yang Ji Chemical Co., Ltd. | Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101361801B (en) * | 2008-09-24 | 2011-06-29 | 胡传良 | Qiancao Naomaitong medicine for treating apoplexy or the like and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1074677C (en) * | 1999-04-29 | 2001-11-14 | 云南白药集团股份有限公司研究所 | Medicine for treating apoplexy and its preparing process |
| KR20020089216A (en) * | 2002-08-19 | 2002-11-29 | 한영환 | The Skin Lightening Cosmetic Composition Containing Extracts of Natural plants And Oriental medicines |
-
2004
- 2004-11-11 CN CNB2004100795560A patent/CN100358530C/en not_active Expired - Fee Related
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009091121A3 (en) * | 2008-01-18 | 2009-09-03 | Yang Ji Chemical Co., Ltd. | Composition comprising the extracts of lysimachia clethroides for prevention and treatment of cardiovascular diseases |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100358530C (en) | 2008-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103349671A (en) | Resveratrol and spirulina composition and preparations and preparation method thereof | |
| CN100345558C (en) | Extract product of general flavone of kudzuvine root, preparation method and application | |
| CN101559066B (en) | Use of beta-galactosides and composition in preparing medicine for myocardial ischemia | |
| CN101040896A (en) | Flavone of astragalus extract, the medicine use and the compound thereof | |
| CN100358530C (en) | Medicine prepn for treating cerebral apoplexy and its prepn | |
| CN1067901C (en) | Drug for curing migraine and its preparing method | |
| CN100486626C (en) | A medicament for treating tension headache and preparation method thereof | |
| CN1233401C (en) | Agastache capsule for restoring healthy energy andits prepn and application | |
| CN1943620B (en) | Chinese medicine composition for treating cardio-cerabral vascular diseases and its preparing method | |
| CN1768770A (en) | Quality control method of agavaceae extract medicinal formulation | |
| CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
| CN1985921A (en) | Chinese medicine composition for treating common cold and its preparing method | |
| CN1322870C (en) | Quality control method for speedwell flavone capsule | |
| CN1634241A (en) | Compound formulation of notoginseng for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1695728A (en) | Oral taking preparation of Chinese traditional medicine for nourishing the kidney and the lung | |
| CN101062108A (en) | Medicinal composition for treating dysmenorrhea and preparation process thereof | |
| CN1284559C (en) | Chinese medicine solid preparation for blood quickening and statis dissipating and its preparation method | |
| CN1386526A (en) | Chinese medicine composition for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1544021A (en) | Chinese traditional medicine preparation Qishenmai for treating coronary heart disease and angina pectoris and its preparing process | |
| CN1911300A (en) | Compound traditional Chinese medicine prepn. for treating chronic reactivation hepatitis B and its prepn. method | |
| CN1733107A (en) | Medicine for treating coronary disease and apoplexy sequelae and process for preparing the same | |
| CN1785252A (en) | Delayed-release compounding tablets contg. red-rooted salvia gel skeleton, and its prepn. method | |
| CN1861158A (en) | Dispersing tablets of Liuwei-dihuang extract or its add-substract components, and its prepn. method | |
| CN1915256A (en) | Medicinal composition, preparation method and quality control method | |
| CN101045099A (en) | Traditional Chinese medicine composition for treating high fever tic |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080102 Termination date: 20211111 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |